Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multiplicom Appoints Board Chairman

Published: Thursday, June 27, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Appointment of Dr Ian Gilham as Chairman of the Board of Directors.

Multiplicom NV has announced that Dr Ian Gilham has been appointed as Chairman of the Board of Directors.

"We are delighted that Ian has decided to join our team, strengthening the Board at this important time in the company’s development” said Dirk Pollet CEO of Multiplicom.

Pollet continued, “Ian has worked with many companies providing them with valuable experience in research, development and the commercialization of products. We look forward to working with him and have every confidence that his expertise will help us grow the company and deliver value for both new and existing investors.”

Dr. Gilham was Chief Executive Officer of Axis-Shield plc, a public in-vitro diagnostics company, until Alere acquired it in November 2011.

Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008.

Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK’s medicines.

Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of clinical diagnostics and pharmaceuticals.

Commenting on his appointment, Dr Ian Gilham said: “It is with great pleasure that I have accepted the opportunity to become Chairman to the Board of Multiplicom. The molecular diagnostics market is undergoing rapid growth, fuelled by the decreasing cost of DNA sequencing and increased availability of genetic information that links genes to health and disease. The outlook is very promising for the genomic and somatic mutations that Multiplicom is focused on. I look forward to working with the Board to make sure the company fulfills its clearly evident potential.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Multiplicom Receives €1.9m Grant
Multiplicom has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers.
Thursday, May 26, 2016
Multiplicom’s BRCA MASTR™ Dx Test Accredited with CE/IVD Mark
BRCA MASTR Dx will be shipped throughout Europe from September 2012.
Wednesday, June 20, 2012
Multiplicom Receives €200,000 Grant for Novel Non-Invasive Pre-Natal Test
IWT grant to support development of early aneuploidy detection during pregnancy.
Thursday, June 07, 2012
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Soil Carbon Release Might Equal U.S. Emissions
Research suggests 55M tons of carbon will be release from soils by 2050, 17% higher than prjected emissions.
Inspiring Futuristic Innovation: Brain ‘Organoids’
Scientists create artificial brains, providing an advanced model for studying brain tumour development.
‘NoBody,’ a Microprotein On a Mission
Researchers identify over 400 microproteins encoded in the human genome, one of which clears unneeded genetic material inside cells.
Unexpected Epigenetic Enzymes Role in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
New Form of Autism Found
An international team of researchers have identified a new form of syndromic autism.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!